BioSpace News Archive

The industry analysis report is considered a valuable source of information about the global Colonoscopy Bowel Preparation Drugs industry and lays stress on the future market scope, emerging industry trends, industry statistics, and market growth potential during the forecast years.

The report further provides details about each segments and regions covered in the global ENT Medical Devices market. The data has been collected through extensive primary and secondary research and is validated by experts in the industry.

The industry analysis report is considered a valuable source of information about the global Interventional Oncology industry and lays stress on the future market scope, emerging industry trends, industry statistics, and market growth potential during the forecast years.

Developed as a therapeutic for neuropathic pain, iQ-008 shows significant effects in all pain models.

A new study by the Centers for Disease Control and Prevention (CDC) and Abt Associates shows that the Pfizer-BioNTech COVID-19 vaccine is moderately effective against the Omicron variant for children ages 5-15.

Opioid science is about to enter its fourth generation according to Lynn Kirkpatrick, CEO of Ensysce Biosciences, a leading biotech company specializing in advanced and highly novel analgesia medicine.

Foghorn® Therapeutics Inc. announced that Foghorn will participate at the 2022 Guggenheim Targeted Protein Degradation Day which is being held virtually on March 16th, 2022.

Kiromic BioPharma, Inc. reported business updates and financial results for its third quarter ending September 30, 2021.

Longeveron Inc. (NASDAQ: LGVN) (the “Company,” “Longeveron” or “we,” “us,” or “our”), a clinical stage biopharmaceutical company developing cellular therapies for chronic, aging-related and life-threatening conditions, today reported recent business highlights and key upcoming catalysts for 2022, and its financial results for the fourth quarter and full year 2021.

Corbus Pharmaceuticals Holdings, Inc. today announcing that Yuval Cohen, Ph.D., Chief Executive Officer of Corbus, will participate in a fireside chat at the Oppenheimer 32nd Annual Healthcare Conference on March 17, 2022 at 8:00 AM ET.